CS419786A2 - Method of grippal vaccine production - Google Patents
Method of grippal vaccine productionInfo
- Publication number
- CS419786A2 CS419786A2 CS864197A CS419786A CS419786A2 CS 419786 A2 CS419786 A2 CS 419786A2 CS 864197 A CS864197 A CS 864197A CS 419786 A CS419786 A CS 419786A CS 419786 A2 CS419786 A2 CS 419786A2
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- vaccine
- complex
- mdp derivative
- particle
- influenza
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/5555—Muramyl dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/829—Liposomes, e.g. encapsulation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP60123341A JPH0688911B2 (ja) | 1985-06-06 | 1985-06-06 | インフルエンザワクチン及びその製造方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CS419786A2 true CS419786A2 (en) | 1989-04-14 |
CS269981B2 CS269981B2 (en) | 1990-05-14 |
Family
ID=14858166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CS864197A CS269981B2 (en) | 1985-06-06 | 1986-06-06 | Method of grippal vaccine production |
Country Status (12)
Country | Link |
---|---|
US (1) | US4826687A (cs) |
EP (1) | EP0205098B1 (cs) |
JP (1) | JPH0688911B2 (cs) |
KR (1) | KR940001373B1 (cs) |
CN (1) | CN1020407C (cs) |
AT (1) | ATE76756T1 (cs) |
AU (1) | AU585353B2 (cs) |
CA (1) | CA1262091A (cs) |
CS (1) | CS269981B2 (cs) |
DE (1) | DE3685519T2 (cs) |
ES (1) | ES8707113A1 (cs) |
SU (1) | SU1651782A3 (cs) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5916588A (en) * | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
US5897873A (en) * | 1984-04-12 | 1999-04-27 | The Liposome Company, Inc. | Affinity associated vaccine |
US6090406A (en) * | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
US5026557A (en) * | 1987-09-09 | 1991-06-25 | The Liposome Company, Inc. | Adjuvant composition |
NZ230423A (en) * | 1988-08-25 | 1993-08-26 | Liposome Co Inc | A dosage form comprising an antigen and a multilamellar liposome comprising dimyristolyphosphatidylcholine (dmpc) and cholesterol |
WO1990001948A1 (en) * | 1988-08-25 | 1990-03-08 | The Liposome Company, Inc. | Influenza vaccine and novel adjuvants |
US5100662A (en) * | 1989-08-23 | 1992-03-31 | The Liposome Company, Inc. | Steroidal liposomes exhibiting enhanced stability |
WO1991011174A1 (en) * | 1990-01-25 | 1991-08-08 | The University Of Colorado Foundation, Inc. | Method for preventing immune suppression in trauma patients |
JP2777258B2 (ja) * | 1990-03-13 | 1998-07-16 | 第一製薬株式会社 | ムラミルジペプチド含有脂質膜構造体 |
US5246707A (en) * | 1990-04-26 | 1993-09-21 | Haynes Duncan H | Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes |
US5091188A (en) * | 1990-04-26 | 1992-02-25 | Haynes Duncan H | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs |
GB9018690D0 (en) * | 1990-08-24 | 1990-10-10 | Wellcome Found | Vaccines |
IL99851A (en) * | 1990-10-30 | 1996-06-18 | Daiichi Seiyaku Co | Moramildipeptide derivatives and an influenza vaccine containing them |
WO1995022989A1 (en) * | 1994-02-24 | 1995-08-31 | Micro-Pak, Inc. | Vaccines containing paucilamellar lipid vesicles as immunological adjuvants |
JP5038552B2 (ja) | 1995-10-17 | 2012-10-03 | オバン・エナジー・リミテッド | 不溶性薬物の送達 |
US6465016B2 (en) | 1996-08-22 | 2002-10-15 | Research Triangle Pharmaceuticals | Cyclosporiine particles |
US7255877B2 (en) * | 1996-08-22 | 2007-08-14 | Jagotec Ag | Fenofibrate microparticles |
ES2201673T3 (es) * | 1998-02-11 | 2004-03-16 | Rtp Pharma Corporation | Combinacion de esteroides y acidos grasos poiinsaturados para el tratamiento de estados inflamatorios. |
US6979456B1 (en) | 1998-04-01 | 2005-12-27 | Jagotec Ag | Anticancer compositions |
AU764001B2 (en) | 1998-05-29 | 2003-08-07 | Skyepharma Canada Inc. | Thermoprotected microparticle compositions and process for terminal steam sterilization thereof |
EP1105096B1 (en) | 1998-08-19 | 2003-10-29 | Skyepharma Canada Inc. | Injectable aqueous dispersions of propofol |
JP4809533B2 (ja) | 1998-11-20 | 2011-11-09 | オバン・エナジー・リミテッド | 分散し得るリン脂質で安定化されたミクロ粒子 |
ATE296091T1 (de) * | 1999-09-21 | 2005-06-15 | Skyepharma Canada Inc | Oberflächenmodifizierte teilchenförmige zusammensetzungen biologisch aktiver stoffe |
JP5102423B2 (ja) | 2000-04-20 | 2012-12-19 | オバン・エナジー・リミテッド | 改善された水不溶性薬剤粒子の処理 |
ATE424811T1 (de) | 2000-08-31 | 2009-03-15 | Jagotec Ag | Gemahlene partikel |
US8586094B2 (en) * | 2000-09-20 | 2013-11-19 | Jagotec Ag | Coated tablets |
NZ525231A (en) * | 2000-09-20 | 2004-08-27 | Skyepharma Canada Inc | Phospholipid stabilised feno-fibrate microparticles for pharmaceutical use |
US6534088B2 (en) * | 2001-02-22 | 2003-03-18 | Skyepharma Canada Inc. | Fibrate-statin combinations with reduced fed-fasted effects |
CA2438942A1 (en) * | 2001-02-23 | 2002-09-26 | Glaxosmithkline Biologicals S.A. | Influenza vaccine formulations for intradermal delivery |
JP2004520144A (ja) * | 2001-04-27 | 2004-07-08 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 新規ワクチン |
BR0210628A (pt) * | 2001-06-29 | 2004-08-10 | Becton Dickinson Co | Liberação intradérmica de vacinas e agentes terapêuticos genéticos via microcânula |
EP2241330A1 (en) | 2003-02-14 | 2010-10-20 | The Curators Of The University Of Missouri | Contraceptive methods and compositions related to proteasomal interference |
US7588774B2 (en) * | 2003-05-12 | 2009-09-15 | Becton, Dickinson And Company | Molecules enhancing dermal delivery of influenza vaccines |
US20050123550A1 (en) * | 2003-05-12 | 2005-06-09 | Laurent Philippe E. | Molecules enhancing dermal delivery of influenza vaccines |
AR056245A1 (es) | 2003-06-19 | 2007-10-03 | Bestewil Holding Bv | Membranas virales reconstituidas funcionales que contienen un coadyuvante |
EP1708742A4 (en) * | 2003-12-05 | 2008-11-05 | Becton Dickinson Co | METHOD FOR IMPROVING THE IMMUNE RESPONSE IN THE INTRADERMAL COMPARTMENT AND USEFUL LINKS THEREFOR |
US20060121055A1 (en) * | 2004-12-06 | 2006-06-08 | Becton, Dickinson And Company, Inc. | Compositions with enhanced immunogenicity |
US7468187B2 (en) | 2005-10-18 | 2008-12-23 | Iowa State University Research Foundation, Inc. | Canine influenza virus and related compositions and methods of use |
CA2680600A1 (en) | 2007-03-12 | 2008-09-18 | Antigen Express, Inc. | Li-rnai involved li suppression in cancer immunotherapy |
EP2278997B1 (en) | 2008-04-21 | 2016-08-10 | Nanobio Corporation | Nanoemulsion influenza vaccine |
EP2729169A1 (en) | 2011-07-06 | 2014-05-14 | Nanobio Corporation | Human respiratory syncytial virus vaccine |
WO2013028738A1 (en) | 2011-08-22 | 2013-02-28 | Nanobio Corporation | Herpes simplex virus nanoemulsion vaccine |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4009258A (en) * | 1972-09-25 | 1977-02-22 | The Mount Sinai School Of Medicine Of The City University Of New York | Influenza vaccine containing a recombinant, antigenically hybridized virus and method of using the same |
CH589453A5 (cs) * | 1974-01-14 | 1977-07-15 | Sandoz Ag | |
US4117113A (en) * | 1974-06-25 | 1978-09-26 | National Research Development Corporation | Immunological preparations |
US4196191A (en) * | 1975-09-29 | 1980-04-01 | Burroughs Wellcome Co. | Biological preparations |
US4261975A (en) * | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
EP0032578B1 (de) * | 1980-01-16 | 1984-07-25 | Hans Georg Prof. Dr. Weder | Verfahren und Dialysiereinrichtung zur Herstellung von Bilayer-Vesikeln und Verwendung der Bilayer-Vesikel |
DE3173713D1 (en) * | 1980-09-05 | 1986-03-20 | Frappier Armand Inst | Formation of an immunosome exclusively made of viral antigens reconstituted on an artificial membrane |
US4327182A (en) * | 1981-01-22 | 1982-04-27 | Connaught Laboratories Incorporated | Purification of influenza sub-unit vaccine |
US4565696A (en) * | 1983-08-03 | 1986-01-21 | The Regents Of The University Of California | Production of immunogens by antigen conjugation to liposomes |
FR2551758B1 (fr) * | 1983-08-16 | 1986-01-31 | Anvar | Derives de muramyl-peptides et de steroides ayant des proprietes d'activation des macrophages |
IL69720A (en) * | 1983-09-14 | 1987-08-31 | Univ Ramot | Anti-tumor pharmaceutical compositions comprising liposome-bound porphyrins |
US4663161A (en) * | 1985-04-22 | 1987-05-05 | Mannino Raphael J | Liposome methods and compositions |
-
1985
- 1985-06-06 JP JP60123341A patent/JPH0688911B2/ja not_active Expired - Lifetime
-
1986
- 1986-05-28 US US06/867,539 patent/US4826687A/en not_active Expired - Fee Related
- 1986-06-04 CA CA000510861A patent/CA1262091A/en not_active Expired
- 1986-06-05 DE DE8686107631T patent/DE3685519T2/de not_active Expired - Fee Related
- 1986-06-05 SU SU864027675A patent/SU1651782A3/ru active
- 1986-06-05 AU AU58365/86A patent/AU585353B2/en not_active Ceased
- 1986-06-05 KR KR1019860004500A patent/KR940001373B1/ko not_active IP Right Cessation
- 1986-06-05 EP EP86107631A patent/EP0205098B1/en not_active Expired - Lifetime
- 1986-06-05 ES ES555748A patent/ES8707113A1/es not_active Expired
- 1986-06-05 AT AT86107631T patent/ATE76756T1/de not_active IP Right Cessation
- 1986-06-06 CS CS864197A patent/CS269981B2/cs unknown
- 1986-06-06 CN CN86103717A patent/CN1020407C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DE3685519D1 (de) | 1992-07-09 |
ES555748A0 (es) | 1987-07-01 |
CS269981B2 (en) | 1990-05-14 |
AU5836586A (en) | 1986-12-18 |
ATE76756T1 (de) | 1992-06-15 |
KR870000075A (ko) | 1987-02-16 |
AU585353B2 (en) | 1989-06-15 |
US4826687A (en) | 1989-05-02 |
CN1020407C (zh) | 1993-05-05 |
CN86103717A (zh) | 1987-02-11 |
ES8707113A1 (es) | 1987-07-01 |
SU1651782A3 (ru) | 1991-05-23 |
KR940001373B1 (ko) | 1994-02-21 |
CA1262091A (en) | 1989-10-03 |
JPH0688911B2 (ja) | 1994-11-09 |
EP0205098A2 (en) | 1986-12-17 |
JPS61282321A (ja) | 1986-12-12 |
EP0205098B1 (en) | 1992-06-03 |
DE3685519T2 (de) | 1993-01-21 |
EP0205098A3 (en) | 1989-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CS419786A2 (en) | Method of grippal vaccine production | |
CA1279012C (en) | Process for preparing immunogenic complexes and pharmaceutical composition containing these complexes | |
AU722647B2 (en) | Protein-lipid vesicles and autogenous vaccine comprising the same | |
DK440386D0 (da) | Laegemiddelholdigt chlorfluorcarbon-aerosoldrivmiddelpraeparat | |
EP0047480B1 (en) | Formation of an immunosome exclusively made of viral antigens reconstituted on an artificial membrane | |
ES8506451A1 (es) | Procedimiento para preparar vacunas polivalentes adsorbidas y liofilizadas | |
DK55891D0 (da) | Matrix med immunomodulerende virkning | |
DE286011T1 (de) | Natuerliches oberflaechenwirksames lungenpraeparat, verfahren zu seiner herstellung und pharmazeutische zusammensetzungen. | |
EP0319557A4 (en) | Reconstituted hdl particles and uses thereof | |
Alving et al. | Cytotoxic T lymphocytes induced by liposomal antigens: mechanisms of immunological presentation | |
CA2352563A1 (en) | Method to produce inactivated w/o emulsion adjuvanted vaccines | |
DE69023648D1 (de) | Herstellung eines virus und reinigung von virenüberzugsproteinen zur impfstoffverwendung. | |
AU4695479A (en) | Purified antigen | |
ATE87467T1 (de) | Pharmazeutische zubereitung. | |
EP0306912A3 (en) | Immunogenic composites capable of selectively inducing antibody production and pharmaceutical compositions employing the same. | |
JPS574913A (en) | Urokinase preparation for oral administration | |
ATE141503T1 (de) | Verfahren zur herstellung von wirkstoffhaltigen wässrigen liposomensuspensionen | |
Ruttkowski et al. | Qualitative and quantitative changes in the antibody producing cell response to lipopolysaccharide induced after incorporation of the antigen into bacterial membrane phospholipid vesicles. | |
Bergers et al. | Critical factors for liposome-incorporated tumour-associated antigens to induce protective tumour immunity to SL2 lymphoma cells in mice | |
SE8400934L (sv) | Forfarande for framstellning av lyofiliserade, adsorberade, polyvalenta vacciner | |
van Dalen et al. | Preparation and characterization of liposomes with incorporated Neisseria gonorrhoeae protein IB and amphiphilic adjuvants | |
WO1991008771A3 (fr) | Procede de culture intensive, in vitro, de souches de babesia divergens, procede de preparation d'exoantigenes et vaccin contenant ces antigenes |